)
Visual
test
Sprint Bioscience
Sprint Bioscience (SPRINT) investor relations material
Sprint Bioscience Q4 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q4 2025 earnings summary11 Feb, 2026
Executive summary
Achieved a transformative year with strengthened financial position and strategic focus, highlighted by the sale of the TREX1 cancer program to Gilead Sciences for $14 million upfront and potential milestones up to $400 million.
Undertook portfolio reprioritization, including staff reductions and program discontinuations, to focus on high-potential projects and cost discipline.
Expanded scientific and commercial partnerships, with positive preclinical data and new collaborations in inflammation and oncology.
Financial highlights
Net revenue for the year was 167.2 MSEK, up from 65.6 MSEK year-over-year; Q4 revenue was 133.9 MSEK, up from 16.3 MSEK.
Operating income for the year reached 97.3 MSEK (previous year: -19.7 MSEK); Q4 operating income was 117.5 MSEK (previous year: -4.9 MSEK).
Net income for the year was 91.7 MSEK (previous year: -18.3 MSEK); Q4 net income was 113.2 MSEK (previous year: -4.2 MSEK).
Earnings per share for the year were 0.99/0.98 SEK (previous year: -0.26 SEK); Q4 EPS was 1.07/1.06 SEK (previous year: -0.06 SEK).
Cash flow from operations for the year was 83.5 MSEK (previous year: -23.4 MSEK); cash at year-end was 126.7 MSEK (previous year: 25.1 MSEK).
Outlook and guidance
Entering 2026 with a strong cash position, focused portfolio, and a clear agenda to drive licensing and partnerships for key programs.
No formal financial forecast provided.
VRK1 reacquisition: new partnering strategy
Impact of PETRA01 termination on portfolio
DCPS biomarker impact on partnering agenda
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Sprint Bioscience
- TREX1 program sold to Gilead for $14M upfront, boosting financials after a loss-making quarter.SPRINT
Q3 202525 Nov 2025 - Early-stage drug discovery innovator leverages partnerships and a broad portfolio for growth.SPRINTLife Science Summit 202519 Nov 2025
- Rights issue completed, VRK1 returned, revenue down, new EDDC partnership for MASH.SPRINTQ2 202527 Aug 2025
- Revenue declined and losses widened in Q3, with significant financing uncertainty ahead.SPRINTQ3 202413 Jun 2025
- Net sales rose sharply and losses narrowed as research milestones and industry interest increased.SPRINTQ2 202413 Jun 2025
- Lower Q1 revenue, cost cuts, and capital raise as VRK1 returns and Petra01 is discontinued.SPRINTQ1 20256 Jun 2025
- Revenue up, losses widen, new AML program launched, funding risk persists.SPRINTQ4 20245 Jun 2025
Next Sprint Bioscience earnings date
Q1 202613 May, 2026
Sprint Bioscience
Next Sprint Bioscience earnings date
Q1 202613 May, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Explore our global coverage